Coronavirus Update: Paxlovid Moves Towards EU Approval, Moderna Targets Omicron
Plus, New China Alliance, Daiichi Assesses mRNA Booster
Pfizer gets European Commission approval for Paxlovid after a positive CHMP opinion, while Moderna started a Phase II study of its Omicron-specific vaccine candidate. Meanwhile, China's Junshi enters into a new oral antiviral collaboration while Daiichi Sankyo investigates its mRNA vaccine contender as a booster shot.
You may also be interested in...
Mankind Pharma has licensed Novartis’ heart failure therapy Entresto in India, executive chairman Ramesh Juneja tells Scrip. The privately-owned company has also acquired the generics business of Panacea in India and Nepal for over $255m.
The European Medicines Agency’s assessment of the oral antiviral combination was conducted under the OPEN Initiative, which involves information sharing among international regulators.
Coronavirus Update: As Pfizer/BioNTech Begin Omicron Vaccine Tests, Regulators Want To Explore Multivalent Route
Pfizer explores options for new vaccine update, Veklury expands to non-hospitalized patients but Regeneron and Lilly therapies stopped in face of Omicron efficacy drop-off.